Columbia Mailman School of Public Health: Women Living With HIV Prefer Long-acting Injectable Anti-Retroviral Therapy Over a Daily Pill
April 24, 2020
April 24, 2020
NEW YORK, April 24 -- Columbia University's Mailman School of Public Health issued the following news:
A new qualitative study by researchers at Columbia University Mailman School of Public Health found that the majority of women living with HIV would endorse a monthly long acting injectable (LAI) antiretroviral therapy over current daily pills. LAI HIV therapy has completed Phase III trials and is awaiting Food and Drug Administration approval.
Study participants were . . .
A new qualitative study by researchers at Columbia University Mailman School of Public Health found that the majority of women living with HIV would endorse a monthly long acting injectable (LAI) antiretroviral therapy over current daily pills. LAI HIV therapy has completed Phase III trials and is awaiting Food and Drug Administration approval.
Study participants were . . .